|
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
RECRUITINGPhase 3Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2026-07-08
Est. completion2030-03
Eligibility
Age10 Years – 17 Years
Healthy vol.Accepted
Locations17 sites
View on ClinicalTrials.gov →
NCT07668336
Summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
Eligibility
Age: 10 Years – 17 YearsHealthy volunteers accepted
Inclusion Criteria: * Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin * Have HbA1c \> 6.5% to ≤ 11.0% at screening * Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of \>85th percentile Exclusion Criteria: * Have type 1 diabetes * After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome * Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening * Have a history of pancreatitis or gallbladder disease * Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) * Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening * Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening
Conditions2
DiabetesDiabetes Mellitus, Type 2
Interventions2
Locations17 sites
Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology
9164261902
Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)
2257632831
Find trials near these locations
Diabetes trials in SacramentoDiabetes trials in San DiegoDiabetes trials in AtlantaDiabetes trials in TulsaDiabetes trials in NashvilleAll trials in CaliforniaAll trials in ConnecticutAll trials in GeorgiaAll trials in IdahoAll trials in KansasAll trials in New YorkAll trials in OklahomaAll trials in PennsylvaniaAll trials in TennesseeAll trials in Texas
Related trials
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) — Eli Lilly and Company
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes — AdventHealth Translational Research Institute
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting — Eli Lilly and Company
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) — Eli Lilly and Company
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity — Eli Lilly and Company
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2026-07-08
Est. completion2030-03
Eligibility
Age10 Years – 17 Years
Healthy vol.Accepted
Locations17 sites
View on ClinicalTrials.gov →
NCT07668336